search
Back to results

Effect of Molecular Hydrogen in Patients With NAFLD (EMoHyNAFLD)

Primary Purpose

Non-Alcoholic Fatty Liver Disease

Status
Completed
Phase
Not Applicable
Locations
Slovakia
Study Type
Interventional
Intervention
HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
placebo
Sponsored by
Comenius University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Alcoholic Fatty Liver Disease focused on measuring Molecular hydrogen, effective antioxidant, oxygen radicals, NAFLD, mitochondria

Eligibility Criteria

33 Years - 69 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • People with age 33-69 years
  • BMI ≥ 25
  • Confirmation of fatty liver by ultrasonographic examination
  • Signed informed consent
  • Alcohol intake according to the AUDIT questionnaire 5 or less points for men or 4 or less points for women

Exclusion Criteria:

  • Unsigned informed consent
  • BMI < 25
  • Presence of severe inflammatory disease with activity (Crohn's disease, ulcerative colitis, active tuberculosis, rheumatoid arthritis, etc.)
  • Presence of acute infectious disease (acute hepatitis, peritonitis, cholecystitis, pancreatitis, etc.)
  • Presence of active neoplastic disease
  • Alcohol intake according to the AUDIT questionnaire more as 5 points for men or more as 4 points for women

Sites / Locations

  • 3rd Department of Internal Medicine Faculty of Medicine Comenius University in Bratislava

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

patients with NAFLD

probands in the control group

Arm Description

17 patients will receive molecular hydrogen

13 probands in the control group who will receive placebo.

Outcomes

Primary Outcome Measures

Changes in body parameters: Weight in kilograms, height in meters, waist circumference in centimeters
The following parameters will be measured for each proband before (time 0) and after the study (time 8 weeks): a) weight and height will be combined to report BMI in kg/m^2, waist circumference in cm.
Changes in blood parameters ALT
ALT (alaninaminotransferase) ukat/L
Changes in blood parameters AST
AST (aspartataminotransferase) ukat/L
Changes in blood parameters ALP
ALP (alkaline phosphatase) ukat/L
Changes in blood parameters GMT
GMT (gamaglutamyltransferase) ukat/L
Changes in blood parameters Albumin
Albumin (g/L)
Changes in blood parameters Cholinesterase
Cholinesterase (ukat/L)
Changes in blood parameters Bilirubin
Bilirubin total (umol/L)
Changes in blood parameters Glucose
Glucose (mmol/L)
Changes in blood parameters Cholesterol
Cholesterol (mmol/L)
Changes in blood parameters Triacylglycerol
Triacylglycerol (mmol/L)
Changes in blood parameters Insulin
Insulin (mIU/L)
Changes in blood parameters HOMA index
HOMA index (calculation)
Changes in blood parameters Leucocytes
Leucocytes (x10^9/L)
Changes in blood parameters Hemoglobin
Hemoglobin (g/L)
Changes in blood parameters Platelets
Platelets (x10^9/L)
Changes in blood parameters TBARS
TBARS (μmol/L)
Changes in blood parameters MDA
MDA (malondialdehyde) (μmol/L)
Changes in blood parameters LDH
LDH (lactatdehydrogenase) (mU/mL)
Changes in blood parameters MMP-2
MMP-2 (matrix metalloproteinase2) (% of change)
Changes in blood parameters MMP-9
MMP-9 (matrix-metalloproteinase 9) (% of change)
Changes in blood parameters 8-OHdG
8-OHdG (8-hydroxy-2-deoxyguanosine) (ng/mL)
Changes in blood parameters SOD
SOD (superoxiddismutase) (ng/mL)
Changes in blood parameters NFkB
NFkB (nuclear factor kappa B) (% of change)
Changes in blood parameters TNF alfa
TNF alfa (tumor necrosis factor alpha) (% of change)
Changes in blood parameters HSP 60
HSP 60 (heat shock protein 60) (% of change)
Changes in blood parameters HSP 70
HSP 70 (heat shock protein 70) (% of change)
Changes in blood parameters Alpha tocopherol
Alpha tocopherol (μmol/L)
Changes in blood parameters Gama tocopherol
Gama tocopherol (μmol/L)
Changes in blood parameters Beta carotene
Beta carotene (μmol/L)
Changes in blood parameters Coenzyme Q 10 in platelets
Coenzyme Q 10 in platelets (pmol/10^9 cells)
Changes in blood parameters Coenzyme Q 10 in plasma
Coenzyme Q 10 in plasma (μmol/L)
Changes in blood parameters Coenzyme Q 10 in whole blood
Coenzyme Q 10 in whole blood (μmol/L)

Secondary Outcome Measures

Full Information

First Posted
May 14, 2021
Last Updated
April 6, 2022
Sponsor
Comenius University
Collaborators
NWN & Drink HRW
search

1. Study Identification

Unique Protocol Identification Number
NCT05325398
Brief Title
Effect of Molecular Hydrogen in Patients With NAFLD
Acronym
EMoHyNAFLD
Official Title
Effect of Molecular Hydrogen in Patients With Non Alcoholic Faty Liver Disease
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
May 1, 2020 (Actual)
Primary Completion Date
December 1, 2020 (Actual)
Study Completion Date
December 18, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Comenius University
Collaborators
NWN & Drink HRW

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective role in many human diseases. Due to their small size and high permeability, H2 is easily transportable into subcellular structures as mitochondria.
Detailed Description
Non-alcoholic fatty liver disease, NAFLD, is the most common cause of liver disease. According to the forecasts, the non-alcoholic steatohepatitis will be the most common cause of liver transplantation and hepatic mortality in 2030. NAFLD is also a significant risk factor for the development of hepatocellular carcinoma, even in the non-cirrhotic stage of liver disease. The prevention of the progression of NAFLD to NASH (nonalcoholic steatohepatitis) is therefore a key factor in preventing this unfavorable prognosis. Obesity and its associated comorbidities are among the most widespread and challenging conditions in the confrontation of the medical profession in the 21st century. The main metabolic consequence of obesity is insulin resistance, which is strongly associated with the storage of triacylglycerols in the liver. Hepatic steatosis may be associated with steatohepatitis, a condition that can lead to liver cirrhosis and, in the final stage, liver transplantation. According to various sources, the incidence of NAFLD in the population is 20-30%, in obese up to 60%, which makes it the most common liver disease. In the USA, it is even 3 times more common than type 2 diabetes mellitus and 5-10 times more common than chronic hepatitis C. The incidence of non-alcoholic steatohepatitis NASH is 2-3% and is now thought to be the cause of up to 80% cryptogenic liver cirrhosis. The risk of developing cirrhosis in patients with simple hepatic steatosis is 1-2% over 8 years. Insulin resistance, which is defined as an elevated HOMA (homeostasis model assessment) index above 1,4, is found in 70% of patients with NAFLD and plays a major role in the accumulation of triacylglycerols TAG (triacylglyceride) in the liver. Through the rise of hormone-sensitive lipase, hyperinsulinemia leads to the hydrolysis of free fatty acids FFA from visceral adipocytes to the portal vein, through which they enter directly into the liver, where they are esterified to TAG. Reducing the production of apolipoprotein B-100, which is an important part of their secretion from the liver into the circulation in the form of VLDL-lipoproteins, is also a potentiating factor in TAG deposition in the liver. Free oxygen radicals ROS (reactive oxygen species), which are formed due to the oxidative stress, are formed directly in the hepatocyte. However, their formation in visceral adipocytes has also been shown to be involved in liver damage. The main site of ROS are mitochondria. In NAFLD, known mitochondrial dysfunction leads to pathological oxidation of FFA (free fatty acid) in peroxisomes and microsomes, making them another source of ROS. ROS, through damage of the mitochondrial membrane by lipoperoxidation and induction of Fas-ligand expression on the hepatocyte, leads to cell apoptosis. By activating stellate cells, a larger amount of extracellular matrix is formed - Mallory's hyaline, which is associated with the formation of balloon degeneration of hepatocytes, that is a typical histological feature of NASH. From the cytokines, TNF-alpha is mainly used. It is formed by hepatocytes due to the increased supply of FFA. The diagnostic process is often random. One of the options for non-invasive measurement of liver fibrosis is transient elastography FibroScan, which is used for direct measurement of liver elasticity or use of noninvasive fibrosis indexes (NFS, Fib-4, APRI etc) as nondirect tools. Initial studies have confirmed that H2 penetrates cell membranes and protects mitochondria and cell nuclei from acute oxidative stress. Several studies have reported the effect of H2 on mitochondrial function. With H2, the investigators protect the potential of the mitochondrial membrane, increase ATP production and reduce organelle swelling. There are at least four possible mechanisms for H2 through which gene expression can be altered through mitochondrial bioenergetics, of which ghrelin is probably the most important. Ghrelin is the hormone responsible for appetite. It reaches its maximum level during hunger. Obestatin has the opposite effect, which in turn suppresses the feeling of hunger. The role of ghrelin as an energy modulator in H2 intervention may be promoted by interaction with expressed glucose transporters, which increase glucose consumption and modulate oxidative phosphorylation in mitochondria. Exercise led to a significant change in ghrelin levels but had no effect on plasma levels of obestatin. Molecular hydrogen has been shown to relieve oxidative stress, have an anti-inflammatory effect and improve lipid, glucose and energy production in patients as well as in animal models of hepatic steatosis and atherosclerosis. The basic molecular mechanisms remain largely unknown. Molecular hydrogen is an effective antioxidant that reduces cytotoxic reactive oxygen radicals, especially the hydroxyl radical. In several previous experiments, the use of hydrogen-enriched water, HRW, has been shown to have antioxidant effects. The effects of hydrogen on the prevention of hepatocarcinogenesis in STAM mice were also investigated. The number of tumors was significantly lower in the HRW groups and the tumors were smaller than in the other groups. The results clearly demonstrated that HRW can be an effective treatment for apoptosis, inflammation and hepatocarcinogenesis in NAFLD. The aim of the study is to verify effectiveness and safety of molecular hydrogen on a group of patients with NAFLD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Alcoholic Fatty Liver Disease
Keywords
Molecular hydrogen, effective antioxidant, oxygen radicals, NAFLD, mitochondria

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
patients with NAFLD
Arm Type
Active Comparator
Arm Description
17 patients will receive molecular hydrogen
Arm Title
probands in the control group
Arm Type
Placebo Comparator
Arm Description
13 probands in the control group who will receive placebo.
Intervention Type
Dietary Supplement
Intervention Name(s)
HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
Intervention Description
The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen. All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours. They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study).
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Intervention Description
13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours. They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)
Primary Outcome Measure Information:
Title
Changes in body parameters: Weight in kilograms, height in meters, waist circumference in centimeters
Description
The following parameters will be measured for each proband before (time 0) and after the study (time 8 weeks): a) weight and height will be combined to report BMI in kg/m^2, waist circumference in cm.
Time Frame
8 weeks
Title
Changes in blood parameters ALT
Description
ALT (alaninaminotransferase) ukat/L
Time Frame
8 weeks
Title
Changes in blood parameters AST
Description
AST (aspartataminotransferase) ukat/L
Time Frame
8 weeks
Title
Changes in blood parameters ALP
Description
ALP (alkaline phosphatase) ukat/L
Time Frame
8 weeks
Title
Changes in blood parameters GMT
Description
GMT (gamaglutamyltransferase) ukat/L
Time Frame
8 weeks
Title
Changes in blood parameters Albumin
Description
Albumin (g/L)
Time Frame
8 weeks
Title
Changes in blood parameters Cholinesterase
Description
Cholinesterase (ukat/L)
Time Frame
8 weeks
Title
Changes in blood parameters Bilirubin
Description
Bilirubin total (umol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Glucose
Description
Glucose (mmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Cholesterol
Description
Cholesterol (mmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Triacylglycerol
Description
Triacylglycerol (mmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Insulin
Description
Insulin (mIU/L)
Time Frame
8 weeks
Title
Changes in blood parameters HOMA index
Description
HOMA index (calculation)
Time Frame
8 weeks
Title
Changes in blood parameters Leucocytes
Description
Leucocytes (x10^9/L)
Time Frame
8 weeks
Title
Changes in blood parameters Hemoglobin
Description
Hemoglobin (g/L)
Time Frame
8 weeks
Title
Changes in blood parameters Platelets
Description
Platelets (x10^9/L)
Time Frame
8 weeks
Title
Changes in blood parameters TBARS
Description
TBARS (μmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters MDA
Description
MDA (malondialdehyde) (μmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters LDH
Description
LDH (lactatdehydrogenase) (mU/mL)
Time Frame
8 weeks
Title
Changes in blood parameters MMP-2
Description
MMP-2 (matrix metalloproteinase2) (% of change)
Time Frame
8 weeks
Title
Changes in blood parameters MMP-9
Description
MMP-9 (matrix-metalloproteinase 9) (% of change)
Time Frame
8 weeks
Title
Changes in blood parameters 8-OHdG
Description
8-OHdG (8-hydroxy-2-deoxyguanosine) (ng/mL)
Time Frame
8 weeks
Title
Changes in blood parameters SOD
Description
SOD (superoxiddismutase) (ng/mL)
Time Frame
8 weeks
Title
Changes in blood parameters NFkB
Description
NFkB (nuclear factor kappa B) (% of change)
Time Frame
8 weeks
Title
Changes in blood parameters TNF alfa
Description
TNF alfa (tumor necrosis factor alpha) (% of change)
Time Frame
8 weeks
Title
Changes in blood parameters HSP 60
Description
HSP 60 (heat shock protein 60) (% of change)
Time Frame
8 weeks
Title
Changes in blood parameters HSP 70
Description
HSP 70 (heat shock protein 70) (% of change)
Time Frame
8 weeks
Title
Changes in blood parameters Alpha tocopherol
Description
Alpha tocopherol (μmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Gama tocopherol
Description
Gama tocopherol (μmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Beta carotene
Description
Beta carotene (μmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Coenzyme Q 10 in platelets
Description
Coenzyme Q 10 in platelets (pmol/10^9 cells)
Time Frame
8 weeks
Title
Changes in blood parameters Coenzyme Q 10 in plasma
Description
Coenzyme Q 10 in plasma (μmol/L)
Time Frame
8 weeks
Title
Changes in blood parameters Coenzyme Q 10 in whole blood
Description
Coenzyme Q 10 in whole blood (μmol/L)
Time Frame
8 weeks
Other Pre-specified Outcome Measures:
Title
Entry check of patients health status- clinical examination SPG and SPL
Description
Entry examination will include: SPG: Status presens generalis (consciousness, body habitus, skin, nutrition), SPL: status presens localis (head, neck, chest, abdomen, limbs)- described generally as number of participants with changes in healt status
Time Frame
2 hours
Title
Entry check of patients health status- urinary sediment
Description
Urinary sediment normal : leucocyte 1-2 , erythrocyte: 0-1, cultivation: negative or bacterial agens more than 10^5 - described generally as number of participants with changes in urinary sedinent status (normal/abnormal)
Time Frame
2 hours
Title
Entry check of patients health status- USG
Description
USG: Ultrasonographic examination: fatty liver: enlargement of the liver more than 130 mm in anteroposterior position, enlarged echogenity of the liver, curved anterior liver lobe. 1 of these parameter is sufficient for diagnosis of fatty liver - described generally as number of participants with changes in urinary sedinent status (normal/abnormal)
Time Frame
2 hours
Title
Entry check of patients health status- Life style risk factors questionnaire
Description
Filling of the following Questionnaire: Life style risk factors questionnaire Part A/ NAFLD score more as 7 points means risk of nonalcoholic fatty liver disease (NAFLD) Minimum: 0 points Maximum: 14 points Part. B/ ALD score (AUDIT C questionnaire) more than 5 points = risk of alcoholic liver disease (ALD) Minimum: 0 points Maximum: 12 points 5 points and more = risk of ALD , risk of worse outcome
Time Frame
1 hours
Title
Entry check of patients health status- AUDIT questionnaire of alcohol intake
Description
Filling of the following Questionnaire: AUDIT questionnaire of alcohol intake Minimum: 0 points Maximum: 40 points 8 points and more= risky alcohol drinking , risk of ALD , risk of worse outcome
Time Frame
30 minutes
Title
Entry check of patients health status- Fast Depression screening by Patient Health Questionnaire
Description
Filling of the following Questionnaire: Fast Depression screening by Patient Health Questionnaire (2 questions) Minimum: 0 points Maximum: 6 points 3 points and more: risk for depression, risk of worse outcome
Time Frame
10 minutes
Title
Entry check of patients health status- Generalized Anxiety Disorder
Description
Filling of the following Questionnaire: Generalized Anxiety Disorder (2 questions) Minimum: 0 points Maximum: 4 points 3 points and more: risk for generalized anxiety disorder, risk of worse outcome
Time Frame
10 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
33 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: People with age 33-69 years BMI ≥ 25 Confirmation of fatty liver by ultrasonographic examination Signed informed consent Alcohol intake according to the AUDIT questionnaire 5 or less points for men or 4 or less points for women Exclusion Criteria: Unsigned informed consent BMI < 25 Presence of severe inflammatory disease with activity (Crohn's disease, ulcerative colitis, active tuberculosis, rheumatoid arthritis, etc.) Presence of acute infectious disease (acute hepatitis, peritonitis, cholecystitis, pancreatitis, etc.) Presence of active neoplastic disease Alcohol intake according to the AUDIT questionnaire more as 5 points for men or more as 4 points for women
Facility Information:
Facility Name
3rd Department of Internal Medicine Faculty of Medicine Comenius University in Bratislava
City
Bratislava
ZIP/Postal Code
83101
Country
Slovakia

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
33164536
Citation
Gvozdjakova A, Klauco F, Kucharska J, Sumbalova Z. Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19? Bratisl Lek Listy. 2020;121(11):775-778. doi: 10.4149/BLL_2020_126.
Results Reference
background
PubMed Identifier
32210203
Citation
Gvozdjakova A, Sumbalova Z, Kucharska J, Komlosi M, Rausova Z, Vancova O, Szamosova M, Mojto V. Platelet Mitochondrial Respiration, Endogenous Coenzyme Q10 and Oxidative Stress in Patients with Chronic Kidney Disease. Diagnostics (Basel). 2020 Mar 23;10(3):176. doi: 10.3390/diagnostics10030176.
Results Reference
background
PubMed Identifier
32955899
Citation
Gvozdjakova A, Kucharska J, Sumbalova Z, Rausova Z, Chladekova A, Komlosi M, Szamosova M, Mojto V. The importance of coenzyme Q10 and its ratio to cholesterol in the progress of chronic kidney diseases linked to non- -communicable diseases. Bratisl Lek Listy. 2020;121(10):693-699. doi: 10.4149/BLL_2020_113.
Results Reference
background
PubMed Identifier
31241044
Citation
Gvozdjakova A, Kucharska J, Sumbalova Z, Nemec M, Chladekova A, Vancova O, Rausova Z, Kubalova M, Kuzmiakova Z, Mojto V. Platelets mitochondrial function depends on CoQ10 concentration in winter, not in spring season. Gen Physiol Biophys. 2019 Jul;38(4):325-334. doi: 10.4149/gpb_2019012. Epub 2019 Jun 26.
Results Reference
background
PubMed Identifier
31475544
Citation
Gvozdjakova A, Sumbalova Z, Kucharska J, Chladekova A, Rausova Z, Vancova O, Komlosi M, Ulicna O, Mojto V. Platelet mitochondrial bioenergetic analysis in patients with nephropathies and non-communicable diseases: a new method. Bratisl Lek Listy. 2019;120(9):630-635. doi: 10.4149/BLL_2019_104.
Results Reference
background

Learn more about this trial

Effect of Molecular Hydrogen in Patients With NAFLD

We'll reach out to this number within 24 hrs